Molecular Docking study, and In vitro Evaluation of Antitumor Activity of Some New Isoxazoline and Pyrazoline Derivatives of Nabumetone against breast cancer cell line (MCF-7)

Main Article Content

Kanar Muthanna Alawad
Monther Faisal Mahdi
Ayad M.R. Raauf

Abstract

A variety of new pyrazolines, isoxazolines, and amide derivatives were designed, synthesized, and tested in vitro for their cytotoxic potential against the breast cancer cell line MCF-7. Nabumetone is a prodrug that is used as non-steroidal anti-inflammatory drug


 


(NSAID). Before synthesis, the Molecular docking program (GOLD suite v. 5.7.1) was used to evaluate the selectivity for ER-α receptor, which demonstrated good agreement with the in vitro findings. Specifically, compounds 1e and 2e that target the ER- α receptor had the greatest PLP fitness values of (75.61 and 73.36), respectively, when compared to the tamoxifen reference medication, which had a PLP fitness of (92.78). The IC50 values for the synthesized compounds revealed that compound (1e) has a high IC50 value of 19 µM against MCF-7, compared to tamoxifen, which has an IC50 value of (18.02) µM.


 

Article Details

Section

Articles

How to Cite

Molecular Docking study, and In vitro Evaluation of Antitumor Activity of Some New Isoxazoline and Pyrazoline Derivatives of Nabumetone against breast cancer cell line (MCF-7). (2022). Al Mustansiriyah Journal of Pharmaceutical Sciences, 22(3), 24-34. https://doi.org/10.32947/ajps.v22i3.886

References

- Sinha T. Tumors: Benign and Malignant. Cancer Ther Oncol Int J. 2018;10(3):1–3. DOI: https://doi.org/10.19080/CTOIJ.2018.10.555790

- Ok Cy, Woda B, Kurian E. The pathology of cancer. In: pieters rs, liebmann j, eds. Cancer concepts: a guidebook for the non- oncologist. Worcester Mu of Mms 2018. Doi: 10. 7191/cancer_concepts. 1023. DOI: https://doi.org/10.7191/cancer_concepts.1023

- Hassanpour SH, Dehghani M, Review of cancer from perspective of molecular, Journal of Cancer Research and Practice (2017), doi: 10.1016/j.jcrpr.2017.07.001. DOI: https://doi.org/10.1016/j.jcrpr.2017.07.001

- Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & dale’s pharmacology. 8th ed. Elsevier Churchill Livingstone. 2014. 676–677 .

- Patel GM, Patel JD. Single Core Osmotic Pump (SCOP): Development of Single Layer Osmotic controlled release tablet for poorly soluble drug. J Pharm Technol Drug Res. 2012;4(1):1–9. DOI: https://doi.org/10.7243/2050-120X-1-1

- Faivre S, Djelloul S, Raymond E. New Paradigms in Anticancer Therapy : Targeting Multiple Signaling Pathways With Kinase Inhibitors. Semin Oncol 33:407-420 © 2006 Elsevier Inc. 2006;407–20. DOI: https://doi.org/10.1053/j.seminoncol.2006.04.005

- Sataloff RT, Johns MM, Kost KM. Quinazolines and Anticancer Activity: A Current Perspectives Mujeeb. 2017;1–96.

- Chaudhary KK, Mishra N. A Review on Molecular Docking: Novel Tool for Drug Discovery. JSM Chem. 2016;4(3):4.

- Chen G, Seukep AJ, Guo M. Recent Advances in Molecular Docking for the Research and Discovery of Potential Marine Drugs. Mar Drugs. 2020;18(11). DOI: https://doi.org/10.3390/md18110545

- Kanar m. Alawad, monther f. Mahdi, ayad m.r. Raauf. Molecular docking, synthesis, characterization and adme studies of some new five-member ring heterocyclic compounds with in vitro antiproliferative evaluation. Journal of hunan university. 2021;48(july):1–23.

- Chang J, Ren H, Zhao M, Chong Y, Zhao W, He Y, et al. Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro. Eur J Med Chem. 2017;138:669–88. DOI: https://doi.org/10.1016/j.ejmech.2017.07.005

- Alvarez J, Shoichet B. Virtual screening in drug discovery. Virtual Screening in Drug Discovery 1st Edition (Pub. LocationBoca Raton). 2005. 57-63 . DOI: https://doi.org/10.1201/9781420028775

- Ciavarella S, Milano A, Dammacco F, Silvestris F. Targeted therapies in cancer. BioDrugs. 2010;24(2):77–88. DOI: https://doi.org/10.2165/11530830-000000000-00000

- Di Martino S, Rainone A, Troise A, Di Paolo M, Pugliese S, Zappavigna S, et al. Overview of Fda-Approved Anti Cancer Drugs Used for Targeted Therapy. World Cancer Res J. 2015;2(3):1–8.

- Lee YT, Tan YJ, Oon CE. Molecular targeted therapy: Treating cancer with specificity. Eur J Pharmacol. 2018;834:188–96. DOI: https://doi.org/10.1016/j.ejphar.2018.07.034

- Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer. 2006;6(9):714–27. DOI: https://doi.org/10.1038/nrc1913

- Mohammed, Ahmed Wahhab, Inam Samih Arif, and Ghaith Ali Jasim. "The Cytotoxic Effect of Metformin on RD Cell Line." Al-Mustansiriyah Journal of Pharmaceutical Sciences (AJPS) 19.1 (2019): 85-94.‏ Doi: https://doi.org/10.32947/ajps.19.01.03 DOI: https://doi.org/10.32947/ajps.v19i1.547

- Adnan, Abdul Muhaimen Amjed, Monther Faisal Mahdi, and Ayad Kareem Khan. "New 2-Methyl Benzimidazole derivatives bearing 4-Thiazolidinone heterocyclic rings: Synthesis, Preliminary pharmacological assessment and docking studies." Research Journal of Pharmacy and Technology 14.3 (2021): 1515-1520.‏ Doi: 10.5958/0974-360X.2021.00269.9. DOI: https://doi.org/10.5958/0974-360X.2021.00269.9

- Mahdi MF, Abaas IS. Cytotoxic Activity of Iraqi Cressa Cretica. Al Mustansiriyah J PharmSci. 2019;19(1):95–102. DOI: https://doi.org/10.32947/ajps.v19i1.548

Similar Articles

You may also start an advanced similarity search for this article.